AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12463460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (phase 3 trial)
Number of subjects: 60
Study 10516691 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-F
Number of subjects: 132
Study 10516691 — intervention group
Group type: EXPERIMENTAL
Intervention: TMG
Number of subjects: 132
Study 10516691 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT-3
Number of subjects: 132
Study 8934143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol Strecker stents
Number of subjects: 48
Study 1930808 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclean procedure (experimental group)
Number of subjects: 42
Study 1930808 — intervention group
Group type: COMPARATOR
Intervention: Usual clean procedure (control group)
Number of subjects: 42
Study 7042559 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine pamoate (single dose of 150 mg)
Number of subjects: 36
Study 7042559 — intervention group
Group type: COMPARATOR
Intervention: Imipramine hydrochloride (divided dose of 150 mg)
Number of subjects: 36
Study 28884884 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 10
Study 28884884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27530741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound tight control strategy targeting clinical and imaging remission
Number of subjects: 238
Study 27530741 — intervention group
Group type: COMPARATOR
Intervention: Conventional tight control strategy targeting clinical remission
Number of subjects: 238
Study 27530741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound tight control arm
Number of subjects: 238
Study 27530741 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 238
Study 24083394 — intervention group
Group type: EXPERIMENTAL
Intervention: attitude-plus-anticipated-regret message
Number of subjects: 245
Study 24083394 — intervention group
Group type: COMPARATOR
Intervention: attitude-only message
Number of subjects: 245
Study 24083394 — intervention group
Group type: COMPARATOR
Intervention: no message exposure
Number of subjects: 245
Study 21938072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannooligosaccharides (MOS) 4 g/day
Number of subjects: 60
Study 21938072 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 60
Study 20683465 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich apple (40g providing 1.43g polyphenols per day)
Number of subjects: 30
Study 20683465 — intervention group
Group type: COMPARATOR
Intervention: Polyphenol-poor apple (40g providing 0.21g polyphenols per day)
Number of subjects: 30
Study 18172173 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (ECX)
Number of subjects: 1002
Study 18172173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (EOX)
Number of subjects: 1002
Study 18172173 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and cisplatin plus fluorouracil (ECF)
Number of subjects: 1002
Study 18172173 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and oxaliplatin plus fluorouracil (EOF)
Number of subjects: 1002
Study 18172173 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and oxaliplatin plus capecitabine (EOX)
Number of subjects: 1002
Study 15892540 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist vibration at 80 Hz
Number of subjects: 0
Study 15892540 — intervention group
Group type: COMPARATOR
Intervention: No wrist vibration (control)
Number of subjects: 0
Study 12610012 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate with the free amino acid/protein mixture (CHO+PRO)
Number of subjects: 20
Study 12610012 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 20
Study 10343192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal carboplatin (CBP) 350 mg/m2 plus intravenous cyclophosphamide (CTX) 600 mg/m2
Number of subjects: 90
Study 10343192 — intervention group
Group type: COMPARATOR
Intervention: Intravenous carboplatin (CBP) 350 mg/m2 plus intravenous cyclophosphamide (CTX) 600 mg/m2
Number of subjects: 90
Study 7548495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg single dose
Number of subjects: 213
Study 1900983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of green coffee extract
Number of subjects: 10
Study 1900983 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) pretreatment (80 mg)
Number of subjects: 10
Study 1900983 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline nonspecific airway hyperresponsiveness to methacholine
Number of subjects: 10
Study 1900983 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 10
Study 7141388 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 18
Study 7141388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31861026 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan-amlodipine single-pill combination (SPC)
Number of subjects: 476
Study 31861026 — intervention group
Group type: COMPARATOR
Intervention: Valsartan and amlodipine combination (Control)
Number of subjects: 476
Study 28891056 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil target-controlled infusion using the Minto model
Number of subjects: 56
Study 28891056 — intervention group
Group type: EXPERIMENTAL
Intervention: Minto model during hypothermic circulatory arrest
Number of subjects: 56
Study 25735200 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed integrative treatment for PTSD/SUD
Number of subjects: 353
Study 25735200 — intervention group
Group type: COMPARATOR
Intervention: Active control psychoeducation course on women's health
Number of subjects: 353
Study 23959519 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV)
Number of subjects: 30
Study 23959519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20569228 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 20569228 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (LD)
Number of subjects: 0
Study 20569228 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) + Levodopa (LD)
Number of subjects: 0
Study 20569228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19376304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 18113
Study 19376304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 18113
Study 19376304 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR 2-3)
Number of subjects: 18113
Study 19376304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (both doses)
Number of subjects: 18113
Study 17079994 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial treatment
Number of subjects: 327
Study 15648729 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial tapping
Number of subjects: 0
Study 15648729 — intervention group
Group type: COMPARATOR
Intervention: Articulatory suppression
Number of subjects: 0
Study 11336370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ropivacaine injection (20 ml of ropivacaine 0.5%)
Number of subjects: 100
Study 11336370 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (control group)
Number of subjects: 100
Study 11336370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ropivacaine injection
Number of subjects: 100
Study 9138046 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group cognitive-behavioral therapy (CBT)
Number of subjects: 46
Study 9138046 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cognitive-behavioral therapy (CBT)
Number of subjects: 46
Study 9138046 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 46
Study 7618614 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma atrial natriuretic factor (ANF)
Number of subjects: 145
Study 7618614 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endothelin
Number of subjects: 145
Study 7618614 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 145
Study 7618614 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ANF
Number of subjects: 145
Study 7618614 — intervention group
Group type: EXPERIMENTAL
Intervention: Killip classification
Number of subjects: 145
Study 2751476 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg twice daily)
Number of subjects: 12
Study 950094 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography
Number of subjects: 60
Study 950094 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography with the Chiba needle
Number of subjects: 60
Study 950094 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography (after initial failure of percutaneous)
Number of subjects: 60
Study 950094 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography (after initial failure of endoscopic)
Number of subjects: 60
Study 950094 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography
Number of subjects: 60
Study 950094 — intervention group
Group type: COMPARATOR
Intervention: Complications after endoscopic retrograde cholangiography
Number of subjects: 60
Study 950094 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications after percutaneous transhepatic cholangiography
Number of subjects: 60
Study 30771727 — intervention group
Group type: EXPERIMENTAL
Intervention: sparse pre‐trained random vector functional link (SP‐RVFL) network
Number of subjects: 0
Study 30771727 — intervention group
Group type: COMPARATOR
Intervention: random vector functional link (RVFL)
Number of subjects: 0
Study 25987796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Alequel™, an autologous protein‐containing colon extract, 3 doses per week for 15 weeks (total of 45 doses)
Number of subjects: 43
Study 25987796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Alequel™, an autologous protein‐containing colon extract
Number of subjects: 43
Study 25987796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 23276620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 12.5 mg
Number of subjects: 0
Study 23276620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 0
Study 23276620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 150 mg
Number of subjects: 0
Study 23276620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 300 mg
Number of subjects: 0
Study 23276620 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 23276620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21466598 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO) diet
Number of subjects: 20
Study 21466598 — intervention group
Group type: COMPARATOR
Intervention: Dairy fat (DF) diet
Number of subjects: 20
Study 18287392 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosolo universal bond enhancer
Number of subjects: 33
Study 18287392 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT primer
Number of subjects: 33
Study 16449370 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 20
Study 16449370 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 20
Study 12953157 — intervention group
Group type: COMPARATOR
Intervention: Ocular Hypertension (OHT)
Number of subjects: 79
Study 12953157 — intervention group
Group type: COMPARATOR
Intervention: Primary Open Angle Glaucoma (POAG)
Number of subjects: 79
Study 10875716 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 160
Study 10875716 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 160
Study 10875716 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron and 1.25 mg droperidol combination
Number of subjects: 160
Study 10875716 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 160
Study 8979387 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual success feedback
Number of subjects: 0
Study 8979387 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual failure feedback
Number of subjects: 0
Study 8979387 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual failure feedback (for low-self-esteem group)
Number of subjects: 0
Study 8979387 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual success feedback (in in-group failure/out-group success condition)
Number of subjects: 0
Study 8979387 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual failure feedback (in in-group failure/out-group success condition)
Number of subjects: 0
Study 8979387 — intervention group
Group type: COMPARATOR
Intervention: Yoked-control observer individuals
Number of subjects: 0
Study 1355599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 80 micrograms/kg
Number of subjects: 62
Study 1355599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 100 micrograms/kg
Number of subjects: 62
Study 1355599 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 500 micrograms/kg
Number of subjects: 62
Study 1355599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 62
Study 1355599 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (administered after vecuronium or atracurium)
Number of subjects: 62
Study 6339331 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (single-dose prophylactic antibiotic)
Number of subjects: 64
Study 6339331 — intervention group
Group type: COMPARATOR
Intervention: Control (no doxycycline)
Number of subjects: 64
Study 30597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication with antimicrobials
Number of subjects: 718
Study 30597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication with antihypertensives or antihyperglycemics
Number of subjects: 718
Study 30597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment with antimicrobials
Number of subjects: 718
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ARV)
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV and LNS
Number of subjects: 535
Study 28851037 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment groups
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal haemoglobin
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk minerals
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately anaemic women
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly anaemic women
Number of subjects: 535
Study 28851037 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant TfR
Number of subjects: 535
Study 27662556 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing cotrimoxazole
Number of subjects: 758
Study 27662556 — intervention group
Group type: COMPARATOR
Intervention: Stopping cotrimoxazole
Number of subjects: 758
Study 24077374 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Torque (CT) stretching
Number of subjects: 23
Study 24077374 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Angle (CA) stretching
Number of subjects: 23
Study 22406059 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser atherectomy
Number of subjects: 98
Study 22406059 — intervention group
Group type: COMPARATOR
Intervention: Control population from the SAFER trial
Number of subjects: 98
Study 19013761 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapies in RCTs
Number of subjects: 6
Study 17166731 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical extended mediastinal lymphadenectomy (TEMLA)
Number of subjects: 41
Study 17166731 — intervention group
Group type: COMPARATOR
Intervention: Standard mediastinoscopy
Number of subjects: 41
Study 16027405 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin + Rosiglitazone
Number of subjects: 0
Study 16027405 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Rosiglitazone
Number of subjects: 0
Study 12213870 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (n = 11)
Number of subjects: 35
Study 12213870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) 60 mg/month (n = 11)
Number of subjects: 35
Study 12213870 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 35
Study 12213870 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with uncontrolled disease (n = 13)
Number of subjects: 35
Study 9823652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavaterm balloon coagulation
Number of subjects: 20
Study 9823652 — intervention group
Group type: COMPARATOR
Intervention: roller-ball endometrium coagulation
Number of subjects: 20
Study 10233220 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea-containing moisturizer applied twice daily for 20 days
Number of subjects: 15
Study 2379229 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 150 mg orally four times daily for seven days
Number of subjects: 106
Study 2379229 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 250 mg orally four times daily for seven days
Number of subjects: 106
Study 78297 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalers used 30 min before inhalation of 100 microgram of beclomethasone dipropionate (B.D.P.)
Number of subjects: 18
Study 78297 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 18
Study 31368583 — intervention group
Group type: EXPERIMENTAL
Intervention: Do More, Feel Better
Number of subjects: 18
Study 31368583 — intervention group
Group type: COMPARATOR
Intervention: Referral to mental health services
Number of subjects: 18
Study 25399552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 418
Study 25399552 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m² every 3 weeks)
Number of subjects: 418
Study 25399552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 418
Study 25399552 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 418
Study 23807124 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 295
Study 23807124 — intervention group
Group type: COMPARATOR
Intervention: Traditional postoperative care (TPC)
Number of subjects: 295
Study 22152871 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) for 1 to 2 months, 20 minutes, 3 times a week
Number of subjects: 39
Study 19218908 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative diagnostic and therapeutic developments
Number of subjects: 0
Study 19218908 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection of early melanoma
Number of subjects: 0
Study 16954710 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% lidocaine gel
Number of subjects: 45
Study 16954710 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear gel
Number of subjects: 45
Study 14722682 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 SPET
Number of subjects: 32
Study 14722682 — intervention group
Group type: COMPARATOR
Intervention: CT/MRI
Number of subjects: 32
Study 11413357 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia + placebo (HP)
Number of subjects: 8
Study 11413357 — intervention group
Group type: COMPARATOR
Intervention: Normoxia + salbutamol (NS)
Number of subjects: 8
Study 11413357 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia + salbutamol (HS)
Number of subjects: 8
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group DBP <= 90 mmHg
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group DBP <= 85 mmHg
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group DBP <= 80 mmHg
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment strategy
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitherapy
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritherapy
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of side effects over time
Number of subjects: 0
Study 9404429 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional influence on side effects
Number of subjects: 0
Study 8236548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (Pravachol)
Number of subjects: 286
Study 8236548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 3524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 199
Study 3524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 199
Study 3524643 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 199
Study 3524643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 199
Study 31928023 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial intervention
Number of subjects: 35
Study 31928023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 35
Study 31928023 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy
Number of subjects: 35
Study 29442086 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen orally 1 h before the endodontic procedure (Group A)
Number of subjects: 120